Authors

  1. Section Editor(s): Jacobson, Joy

Article Content

A postlicensing safety analysis of the cervical cancer vaccine Gardasil in the August 19 JAMA examined data from the U.S. Vaccine Adverse Event Reporting System (VAERS) for Gardasil and found that the vaccine's safety profile is consistent with prelicense data, with the exception of a disproportionate reporting of syncope and venous thromboembolic events. The authors advise against using VAERS data to prove an association between the vaccine and subsequent adverse events; monitoring of the vaccine will continue.